Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients

Metastatic Melanoma Clinical Trial

— IMPemBra  

Official title:

Phase 2 Study Comparing Pembrolizumab With Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in Patients Harboring the BRAFV600 Mutation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02625337
• Other study ID #: N15IMP
• Status: Recruiting
• Phase: Phase 2
• First received: December 1, 2015
• Last updated: September 14, 2017
• Start date: January 2016
• Est. completion date: December 2018

Study information

• Verified date: September 2017
• Source: The Netherlands Cancer Institute
• Contact: Christian U. Blank, Prof.
• Phone: +31205122570
• Email: c.blank[@]nki.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2 trial consisting of 24 patients receiving the combination of dabrafenib + trametinib + pembrolizumab in 3 different dosing schemes and 8 patients receiving pembrolizumab standard monotherapy. All patients start with pembrolizumab standard therapy for 6 weeks and will then be randomized to continue pembrolizumab monotherapy or to receive additional intermitted/short-term dabrafenib + trametinib.

Stratification will be baseline LDH level and baseline PD-L1 expression.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: December 2018
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults at least 18 years of age

• World Health Organization (WHO) Performance Status 0-2

• Histologically/cytologically confirmed stage IV BRAF V600E or K metastatic melanoma

• Measurable disease according to RECIST 1.1

• At least one easy accessible lesion (s.c., lymph node) that can be repeatedly biopsied

• Patient willing to undergo triple tumor biopsies during screening, at week 6, week 8 (cohorts 2-4 only), week 12, at week 18, and in case of disease progression.

• No prior immunotherapy targeting PD-1 or PD-L1 (CTLA-4 targeting therapy is allowed)

• No prior BRAF and/or MEK targeting therapy

• No immunosuppressive medications

• Screening laboratory values must meet the following criteria:

WBC = 2.0x109/L, Neutrophils = 1.0x109/L, Platelets = 100 x109/L, Hemoglobin = 5.0 mmol/L Creatinine = 2x ULN AST, ALT = 2.5 x ULN (=5 x ULN for patients with liver metastases) Bilirubin =2 X ULN

• Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

• Women of child bearing potential must agree to use a reliable form of contraceptive during the study treatment period and for at least 120 days following the last dose of study drug

• Men must agree to the use of male contraception during the study Treatment Period and for at least 180 days after the last dose of study drug.

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from this study:

• Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.

• Presence of symptomatic brain or leptomeningeal metastases; patients with asymptomatic brain metastases detected during screening for this study are allowed to participate in this study

• Prior PD-1/PD-L1 targeting immunotherapy

• Has an active automimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.

• Has had a prior monoclonal antibody within 4 weeks prior to study day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.

• Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent.

• Note: Subjects with = Grade 2 neuropathy are an exception to this criterion and may qualify for the study.

• Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

• Has evidence of interstitial lung disease or active, non-infectious pneumonitis.

• Known history of Human Immunodeficiency Virus;

• Active infection requiring therapy, positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA);

• Has active tuberculosis

• Has received a live vaccine within 30 days prior to the first dose of trial treatment.

• Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. Patients that have had another malignancy, but are free of tumor for more than 2 years are allowed for inclusion.

Related Conditions & MeSH terms

• Melanoma
• Metastatic Melanoma

Intervention

Drug:
• Pembrolizumab

• Dabrafenib

• Trametinib

Procedure:
• Biopsy
Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
• Blood taking
Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.

Locations

Country	Name	City	State
Netherlands	Antoni van Leeuwenhoek ziekenhuis	Amsterdam	NH

Sponsors (2)

Lead Sponsor	Collaborator
The Netherlands Cancer Institute	Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To describe time to progression beginning from week 12 (cohorts 2-4).	As the short addition of dabrafenib+trametinib will induce for short time tumor regressions we will analyze cohorts 2-4 with a second baseline, namely the end of the targeted therapy at week 12, for progression free survival using to RECIST 1.1	Randomisation until week 12.
Other	Changes of immune parameters within the tumor.	In addition to the primary readout (broadening of the melanoma-specific T cell response in peripheral blood), we will analyze the effect of the different therapy schemes on tumor immune cell infiltration (IHC for CD3, CD4, CD8, CD68, FoxP3, PD-L1, PD-L2, PD-1, CD11b, HLA).	18 weeks from baseline.
Primary	Safety of different schemes of continuous/intermittent dabrafenib+trametinib during treatment with pembrolizumab as compared to pembrolizumab monotherapy as measured by SUSARs.	Safety as measured by SUSARs during treatment week 0 till week 18.	18 weeks from baseline
Primary	Feasibility of different schemes of continuous/intermittent dabrafenib+trametinib during treatment with pembrolizumab as compared to pembrolizumab monotherapy as measured by adherence to the timelines in the study protocol.	Feasibility as measured by adherence to the timelines in the study protocol (week 0 till week 18).	18 weeks from baseline.
Primary	The immune-activating capacity of different schemes of continuous/intermittent dabrafenib+trametinib during treatment with pembrolizumab as compared to pembrolizumab monotherapy	Readout will be the alterations in magnitude or breadth of the self-antigen specific T cell responses in the time interval pre-treatment to week 18 intrapatient, and interpatient, pembrolizumab only (cohort 1) versus pembrolizumab plus intermittent dabrafenib/ trametinib (cohorts 2-4). To this purpose, we will analyze melanoma antigen-specific T cells responses by HLA-A2-restricted MHC-tetramer staining.	18 weeks from baseline.
Secondary	To determine rates of response at week 6, 12, week 18.	Rates of response at week 6, week 12, week 18 according to RECIST 1.1 criteria	Screening, week 6, 12 and 18
Secondary	To determine progression-free survival starting from randomization.	Progression-free survival (PFS) starting from randomization to progression using RECIST 1.1 criteria.	From randomisation until PD, median 10 months.
Secondary	Long-term toxicities of intermittent dabrafenib + trametinib during treatment with pembrolizumab as compared to pembrolizumab monotherapy	Rate and type of late adverse events	From beyond week 18, up to 2 years follow-up.